Squarepoint Ops LLC decreased its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 66.5% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 38,521 shares of the company's stock after selling 76,385 shares during the quarter. Squarepoint Ops LLC's holdings in MiMedx Group were worth $371,000 at the end of the most recent reporting period.
Other large investors have also made changes to their positions in the company. IMG Wealth Management Inc. bought a new stake in shares of MiMedx Group in the 4th quarter worth about $28,000. Van ECK Associates Corp bought a new stake in shares of MiMedx Group in the 4th quarter worth about $40,000. Tower Research Capital LLC TRC grew its holdings in shares of MiMedx Group by 77.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock worth $63,000 after purchasing an additional 2,837 shares during the last quarter. AlphaQuest LLC bought a new stake in shares of MiMedx Group in the 4th quarter worth about $88,000. Finally, Koss Olinger Consulting LLC bought a new stake in MiMedx Group during the 4th quarter worth about $100,000. Institutional investors own 79.15% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts have commented on MDXG shares. Wall Street Zen lowered shares of MiMedx Group from a "strong-buy" rating to a "buy" rating in a report on Friday, May 9th. Cantor Fitzgerald reissued an "overweight" rating and set a $13.00 price objective on shares of MiMedx Group in a report on Thursday, February 27th.
View Our Latest Stock Analysis on MiMedx Group
MiMedx Group Stock Down 1.2%
Shares of NASDAQ:MDXG opened at $6.34 on Friday. MiMedx Group, Inc. has a 12 month low of $5.47 and a 12 month high of $10.14. The company's 50-day moving average price is $6.85 and its two-hundred day moving average price is $8.07. The company has a quick ratio of 3.53, a current ratio of 4.10 and a debt-to-equity ratio of 0.10. The firm has a market cap of $936.43 million, a P/E ratio of 11.53 and a beta of 1.82.
MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 EPS for the quarter, hitting analysts' consensus estimates of $0.06. MiMedx Group had a net margin of 23.86% and a return on equity of 26.21%. The firm had revenue of $88.21 million for the quarter, compared to analyst estimates of $86.32 million. As a group, research analysts forecast that MiMedx Group, Inc. will post 0.3 EPS for the current fiscal year.
Insider Activity
In other MiMedx Group news, CEO Joseph H. Capper bought 200,000 shares of MiMedx Group stock in a transaction dated Friday, May 2nd. The shares were bought at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the purchase, the chief executive officer now owns 529,530 shares of the company's stock, valued at $3,357,220.20. This trade represents a 60.69% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Kimberly Maersk-Moller sold 4,106 shares of the firm's stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total transaction of $32,396.34. Following the completion of the transaction, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. This trade represents a 1.30% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 141,907 shares of company stock valued at $1,112,580. 1.70% of the stock is currently owned by insiders.
About MiMedx Group
(
Free Report)
MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.
Read More
Want to see what other hedge funds are holding MDXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MiMedx Group, Inc. (NASDAQ:MDXG - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider MiMedx Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiMedx Group wasn't on the list.
While MiMedx Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
